Skip to main content
Clinical Trials/NCT02316236
NCT02316236
Completed
Not Applicable

Effect of Dexmedetomidine on Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery

Air Force Military Medical University, China1 site in 1 country66 target enrollmentDecember 10, 2014

Overview

Phase
Not Applicable
Intervention
dexmedetomidine
Conditions
Anesthesia
Sponsor
Air Force Military Medical University, China
Enrollment
66
Locations
1
Primary Endpoint
Richmond Score
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The study is to observe whether dexmedetomidine could reduce agitation during emergence from general anesthesia in patients undergoing retroperitoneal laparoscopic surgery.

Detailed Description

Agitation during emergence is frequent after retroperitoneal urologic surgery. Dexmedetomidine is alpha-2 receptor agonist which shows sedative and algesic effect. In this study we will compare the effect of dexmedetomidine given by different protocols on emergence agitation.

Registry
clinicaltrials.gov
Start Date
December 10, 2014
End Date
August 13, 2015
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Air Force Military Medical University, China
Responsible Party
Principal Investigator
Principal Investigator

Zhihong LU

Dr

Air Force Military Medical University, China

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for retroperitoneal laparoscopic surgery
  • Patients with written informed consent

Exclusion Criteria

  • Patients with difficulty of communication
  • Patients with risk of obstructive sleeping apnea syndrome

Arms & Interventions

dexmedetomidine loading dose

dexmedetomidine is given at load dose

Intervention: dexmedetomidine

dexmedetomidine loading dose

dexmedetomidine is given at load dose

Intervention: loading dose

dexmedetomidine sustaining dose

dexmedetomidine is given at sustaining dose

Intervention: dexmedetomidine

dexmedetomidine sustaining dose

dexmedetomidine is given at sustaining dose

Intervention: sustaining dose

Outcomes

Primary Outcomes

Richmond Score

Time Frame: From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour

Secondary Outcomes

  • Time to awake(From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour)
  • Cough score(From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour)

Study Sites (1)

Loading locations...

Similar Trials